MedTrace Logo

Patient-Reported Outcome Of Facial Erythema (PROOF)

NCT01885000 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2021-08-25

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness). The feedback of patients receiving the active drug will be compared to the feedback of patients receiving the placebo.

Conditions

  • Rosacea
  • Erythema

Interventions

DRUG

Brimonidine tartrate was applied cutaneously once daily for 8 days.

DRUG

Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-01
Primary Completion
2013-11-14
Completion
2013-11-14

Countries

  • Germany
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01885000 on ClinicalTrials.gov